---
title: "再生元制药因高剂量 Eylea 推动的强劲第二季度业绩而股价上涨"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/294356445.md"
description: "再生元制药（REGN）在盘前交易中股价上涨，此前该公司公布的 2026 年第二季度业绩超出市场预期。公司营收达到 42 亿美元，主要得益于其新型高剂量 Eylea 眼部治疗的强劲销售"
datetime: "2026-07-30T11:32:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294356445.md)
  - [en](https://longbridge.com/en/news/294356445.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294356445.md)
generator: "portal-rs"
---

# 再生元制药因高剂量 Eylea 推动的强劲第二季度业绩而股价上涨

Shares of Regeneron Pharmaceuticals (REGN) gained in the premarket on Thursday after the U.S. drugmaker reported Q2 2026 results exceeding the Street estimates comfortably, mainly due to higher sales from the new high-dose version of its eye therapy, Eylea. The Tarrytown, New York-based firm reported $4.2B in revenue for the quarter, indicating ~17...

### 相关股票

- [REGN.US](https://longbridge.com/zh-CN/quote/REGN.US.md)

## 相关资讯与研究

- [一周回顾 | 再生元制药累跌 4.78%，一致目标价高于现价](https://longbridge.com/zh-CN/news/297390430.md)
- [10:07 ET 再生元制药投资者警示：再生元制药公司证券集体诉讼通知 - 请联系 SueWallSt](https://longbridge.com/zh-CN/news/297926980.md)
- [再生元制药宣布 2026 年第三季度每单位股息为 0.05 雷亚尔](https://longbridge.com/zh-CN/news/297814808.md)
- [B. Metzler seel. Sohn & Co. AG 增持了再生元制药公司（Regeneron Pharmaceuticals, Inc.）的股票 $REGN](https://longbridge.com/zh-CN/news/298098855.md)
- [再生元制药董事 Kathryn Guarini 出售了价值 34 万美元的 400 股普通股票](https://longbridge.com/zh-CN/news/297957662.md)

---
> **免责声明: 本文仅供参考，不构成任何投资建议。**